• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

4.070 -0.100 (-2.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
August 11, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
July 23, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations
July 02, 2026
TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced... 
Via MediaOutReach
Topics Economy
News headline image
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
July 02, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
June 22, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
May 14, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
May 11, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
May 04, 2026
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million 
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
February 26, 2026
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
February 23, 2026
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer 
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
November 06, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
August 13, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of “FOCUSfactor®” Energy Drink – More Stocks Moving Inside
June 10, 2025
Via AB Newswire
News headline image
Power Metallic (TSXV: PNPN) (OTCQB: PNPNF) Positioned for Critical Minerals Breakout Following Acquisition – More Stocks Inside
June 10, 2025
Via AB Newswire
News headline image
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
June 10, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
June 03, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Date of First Quarter 2025 Financial Results
May 06, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conference
May 01, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
March 06, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
February 27, 2025
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 10, 2024
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conference
December 02, 2024
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics to Participate in Upcoming Investor Conferences
November 06, 2024
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Leadership Transition
October 30, 2024
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 29, 2024
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
October 22, 2024
From TerSera Therapeutics LLC
Via Business Wire
News headline image
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
September 24, 2024
From The Schall Law Firm
Via Business Wire
News headline image
MGNX DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action – MGNX
September 23, 2024
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap